Top Story

FDA grants breakthrough therapy designation to obeticholic acid for NASH

January 30, 2015

The FDA has granted breakthrough therapy designation to Intercept Pharmaceutical’s obeticholic acid, a potential therapy to treat nonalcoholic steatohepatitis with liver fibrosis, according to a news release from the drugmaker.

Obeticholic acid is a bile acid analog and first-in-class agonist of the farnesoid X receptor, according to the release. It is currently being developed for nonalcoholic steatohepatitis (NASH), primary biliary cirrhosis and primary sclerosing cholangitis.  

The Liver Meeting 2014: The Take Home Meeting News Coverage

The Liver Meeting 2014: The Take Home

January 30, 2015
Every year at The Liver Meeting, an international group of experts convene to discuss the latest in hepatology. HCV Next had the opportunity to sit down with leading…
In the Journals

Daclatasvir with PEG-IFN a-2a/ribavirin reduced treatment time for HCV

January 30, 2015
In a phase 2b clinical trial, a regimen of daclatasvir combined with pegylated interferon alfa-2a and ribavirin was safe and generally well tolerated among patients with…
In the Journals

Supersonic shear imaging accurate in staging liver fibrosis

January 29, 2015
Supersonic shear imaging accurately measured various stages of liver fibrosis, but was not correlated with steatosis or any other liver disease activity, according to…
Low serum sodium, high MELD score increased liver transplant survival In the Journals

Low serum sodium, high MELD score increased liver transplant survival

January 29, 2015
Liver transplant candidates with low serum sodium levels and a MELD score greater than 11 had an increased survival benefit after transplantation, according to new study…
More News Headlines »
CME
HCV Consults: Volume 1, Number 3

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
Meeting News Coverage Video
thumbnail for video 3895262652001

Early liver transplantation could improve survival rates for patients with alcoholic hepatitis

November 17, 2014
BOSTON — Ibrahim A. Hanouneh, MD, hepatologist at Cleveland Clinic, discussed results of a study that compared…
More »
CME
HCV Consults: Volume 1, Number 2

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »
morganatic-roan